Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. - Wikidata - awgldk - TriplyDB

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

http://www.wikidata.org/entity/Q37660341

about

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy Other targeted drugs in melanoma Melanoma: oncogenic drivers and the immune system Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Pathways and therapeutic targets in melanoma Raf-interactome in tuning the complexity and diversity of Raf function.Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance Recent advances in the biology of human circulating tumour cells and metastasis Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination therapy Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors Melanoma: clinical features and genomic insights.Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.The MAPK pathway as an apoptosis enhancer in melanoma.Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells Predictive biomarkers for dasatinib treatment in melanoma.Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas Phenotype switching in melanoma: implications for progression and therapy.EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.OECI-EACR precision medicine for cancer: Conference report 1-4 March 2015, Luxembourg.IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma.Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.MITF Modulates Therapeutic Resistance through EGFR Signaling.

P2860

Q26744335-18CEBB33-7D12-4389-A59B-85D8F857F494 Q26747247-CC68271C-BD88-441C-9DC0-1A8E19505609 Q26771192-7052138B-CC06-4C10-987F-207724738E3C Q26775594-3CB1C3A8-A13B-4354-8C33-56B9EC2C4D36 Q26775598-971EA257-73DA-4716-AD06-E839FAEA2E97 Q26782222-E77B8AF0-43D9-4364-8FA7-553E5442C347 Q26865736-E9C96726-97C8-47E1-B2C6-658BF5BA2AE3 Q27692653-4E80D666-19B2-44D8-A410-8CA84A89225B Q27852994-74460C3E-D6B3-4B5D-81F2-AFC1B8577FAC Q27853210-A18ED232-B854-42DF-B213-3D0C49C7AEDA Q28070120-55048963-8DE5-4A38-A8E4-06AF8D815810 Q28115758-B393C85B-B48A-45E0-AD54-4719AAE2FCC1 Q28468571-CA7EA5CA-ABF0-4538-9476-9BD0666B086A Q28548302-325308BF-F8B6-4915-AF0C-8BFB08240712 Q28818626-AD05CB71-8F64-4442-B80B-951305947C17 Q29542169-5306A364-47B6-46DD-BC26-49C1E0EEE8DF Q30277902-20B1EDD1-95E6-42BD-BA1E-8DCB7DC3D034 Q33713373-A181E615-24C1-4883-BC3E-CA1B11A2B4BC Q33784436-E93FE1E2-86AE-4675-862D-0C33F1DE4457 Q34083191-FA987C3F-91B6-4B74-A8B0-01290CE4C9FA Q34100838-A823894E-2E3E-4978-83BC-1EB5BD7E72E8 Q34104135-1339EF11-9EE7-4FB6-AC20-88EBF51E42B2 Q34662717-0FCEDACD-2ADD-4606-A544-9A014563D1B1 Q34667825-8F31436E-5DE1-4433-A129-D94F4B953790 Q34722210-D0B769D1-C686-419F-B383-F4FA5A12C5B8 Q34781153-CACA5318-768D-46BD-949C-69B4F71A4324 Q34786402-AB8A3A19-3498-4FE2-A629-9A9539E0283F Q34978580-867346A5-2B7E-4B1A-979E-8B8B63135434 Q34990555-2A2422A8-514B-43B6-8BE8-1A7259268589 Q35018167-EC03B581-EE12-4B27-89B4-2DBC2697F625 Q35081779-AF9ED780-D3B3-49F6-9932-B1167B8B6F18 Q35163679-4AAE9851-A289-410A-893C-E0585B35DC5F Q35251663-E99198A2-EAE6-43D7-B7E8-605EEB96FB8B Q35320304-29FCE5C8-5081-4000-8A20-047971C911E9 Q35496363-3ED3453B-746D-42E0-A175-0B476EDD9D75 Q35555492-2AC7E1AC-DD0C-4CE3-B90B-E5E762EC2912 Q35597799-CE8C21FF-E647-4E85-B1D9-F063104BAB11 Q35609071-793AE152-E5E2-4F6B-A8A6-5D900C349A58 Q35619558-95F0C69F-DA0E-4E69-BD95-B776A716AC4E Q35738447-BB69A1F0-1A49-4C45-A87C-F276C52F019F

P2860

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

http://www.wikidata.org/entity/Q37660341

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 December 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Inhibiting EGF receptor or SRC ...... ibitor resistance in melanoma.

@en

Inhibiting EGF receptor or SRC ...... ibitor resistance in melanoma.

@nl

type

label

Inhibiting EGF receptor or SRC ...... ibitor resistance in melanoma.

@en

Inhibiting EGF receptor or SRC ...... ibitor resistance in melanoma.

@nl

prefLabel

Inhibiting EGF receptor or SRC ...... ibitor resistance in melanoma.

@en

Inhibiting EGF receptor or SRC ...... ibitor resistance in melanoma.

@nl

P1433

Q37660341-A83569E6-7543-4779-9259-ADFE460A9EFD

P1476

Q37660341-73ED915B-7111-49C6-B158-7904936F8D20

P2093

Q37660341-02948A3A-E4D7-4040-8DA1-7BEB73D5EA30

Q37660341-1FAD2DA2-6FF3-41B9-93F6-4BC7FD486745

Q37660341-5F5DCE12-0B94-4756-80C8-381A954333D1

Q37660341-6E12C50D-61AB-4437-BF28-793FDA8624C5

Q37660341-759B1182-FA60-4D38-A8EF-D4950E0CA203

Q37660341-86DC1759-5BA6-4903-8D2B-3A7C7B5ED959

Q37660341-A1B09B86-A7B2-42F2-B26B-903AF1E6D1D3

Q37660341-AA2CA178-8CEA-4008-8E9A-30E4EB9527F9

Q37660341-BADFD117-9872-47F8-951C-DC02B37CDF8B

Q37660341-F13B19BF-AE23-4B9A-83A7-B6317FB807A7

P2860

Q37660341-01227758-11F9-4564-A8E6-33BAAB18F2F6

Q37660341-028DF4DE-7232-44A0-8789-464F980777EA

Q37660341-1BF603C4-536F-4A4E-801F-823C7762E5A6

Q37660341-21D06EAE-9D0E-4406-935D-E2CF89879CFB

Q37660341-2491FA87-574B-4BBA-B8F9-385A98B359E0

Q37660341-25886590-A995-4852-A13F-B252F76EF402

Q37660341-35BAF5B1-A4FC-480F-B2C8-2E2E3DFEB5CC

Q37660341-452070EE-AE98-4A00-9F3D-CDC462703488

Q37660341-49579A63-E604-4244-9DDD-6E6BBF452903

Q37660341-5947E317-F27F-47C5-B768-BDE7BBF4F535

P304

Q37660341-2ED35FD0-084A-4E7E-96FB-231DCF628E90

P31

Q37660341-7DD2BCAC-781E-4BC1-A323-881556E87830

P356

Q37660341-90121DEC-3A78-43FC-B09A-D7954ACAA875

P433

Q37660341-3FB90744-89A5-4A6C-AD9D-953519DCDBCA

P478

Q37660341-CC9B3D00-728B-401F-81BD-3B6B8DE24D1F

P50

Q37660341-52407A8F-17FF-414E-807C-6FEB306E3D0E

Q37660341-799BDE41-CA31-4A48-BBAD-FDA595986ABA

Q37660341-D7F0D076-4ACE-428A-BB30-1C8AB0CBD4F9

Q37660341-EC96D24A-EF86-4D55-9503-EEE70AAC6D43

Q37660341-F5122719-FA35-458A-91C2-CA91CBE828EB

P577

Q37660341-52283DB3-E171-4878-BC9D-C94392A77C5A

P5875

Q37660341-798F8B97-4E2C-4617-BD8A-297BC3119740

P698

Q37660341-C290E002-8936-4E66-AACB-37FBEF782190

P932

Q37660341-F903F6BD-4F8C-4053-A652-7AC7924626D8

P356

2159-8290.CD-12-0386

P1433

Cancer Discovery

P1476

Inhibiting EGF receptor or SRC ...... ibitor resistance in melanoma.

@en

P2093

Amaya Viros

http://www.w3.org/2001/XMLSchema#string

Andrew Hayes

http://www.w3.org/2001/XMLSchema#string

Claus Jorgensen

http://www.w3.org/2001/XMLSchema#string

Dan Niculescu-Duvaz

http://www.w3.org/2001/XMLSchema#string

James Larkin

http://www.w3.org/2001/XMLSchema#string

John Sinclair

http://www.w3.org/2001/XMLSchema#string

Malin Pedersen

http://www.w3.org/2001/XMLSchema#string

Maria R Girotti

http://www.w3.org/2001/XMLSchema#string

Martin Gore

http://www.w3.org/2001/XMLSchema#string

Samra Turajlic

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Chk1 phosphorylates the tumour suppressor Mig-6, regulating the activation of EGF signalling

The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity

Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

STRING 8--a global view on proteins and their functional interactions in 630 organisms

DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists

P304

158-167

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-12-0386

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Berta Sanchez-Laorden

Caroline J Springer

P577

2012-12-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233931223

http://www.w3.org/2001/XMLSchema#string

P698

23242808

http://www.w3.org/2001/XMLSchema#string

P932

5321574

http://www.w3.org/2001/XMLSchema#string